Clinical Trial Update: Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN) [Phase 2, Phase 3]

View source ↗

Summary

The TALISMAN trial evaluating tenecteplase versus alteplase for ischemic stroke (Phase 2/3) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Activase (alteplase)
• TNKASE (tenecteplase)

Snippet

Sponsor: Reza Behrouz, DO | Conditions: Ischemic Stroke | Phase 2, Phase 3 | Status: WITHDRAWN